

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 September 2024 (06.09.2024)



(10) International Publication Number
WO 2024/179491 A1

(51) International Patent Classification:

A61P 3/10 (2006.01) C07D 403/12 (2006.01)
A61P 25/28 (2006.01) C07D 405/12 (2006.01)
A61P 35/00 (2006.01) C07D 413/12 (2006.01)
C07D 223/08 (2006.01) C07D 417/12 (2006.01)
C07D 401/12 (2006.01) A61K 31/55 (2006.01)

(21) International Application Number:

PCT/CN2024/078906

(22) International Filing Date:

28 February 2024 (28.02.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2023/079232

02 March 2023 (02.03.2023) CN

(71) Applicant: **ONO PHARMACEUTICAL CO., LTD.**
[JP/JP]; 1-5, Doshomachi 2-chome, Chuo-ku, Osaka-shi,
Osaka 541-8526 (JP).

(71) Applicant (for MG only): **WUXI APPTec (SHANGHAI)
CO., LTD.** [CN/CN]; Building No. 1, 288 Fute Zhong
Road, China (Shanghai) Pilot Free Trade Zone, Pudong
New Area, Shanghai 200131 (CN).

(72) Inventors: **KONDO, Takashi**; c/o Ono Pharmaceutical
Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishi-
ma-gun, Osaka 618-8585 (JP). **TAKEUCHI, Jun**; c/o Ono
Pharmaceutical Co., Ltd., 1-1, Sakurai 3-chome, Shimamo-
to-cho, Mishima-gun, Osaka 618-8585 (JP). **KATO, At-
sushi**; c/o Department Of Hospital Pharmacy, University
Of Toyama, 2630 Sugitani, Toyama-shi, Toyama 930-0194
(JP).

(74) Agent: **LIU, SHEN & ASSOCIATES**; 10th Floor, Build-
ing 1, 10 Caihefang Road, Haidian District, Beijing 100080
(CN).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,


HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: GBA1 AND GCS DUAL MODULATOR



(57) Abstract: A compound represented by formula (I) or a pharmaceuti-
cally acceptable salt thereof is provided, which is useful as a pharmaceutical in-
gredient having GBA1 and GCS dual modulatory activity in the prevention
and/or treatment of a disease associated with GBA1 and/or GCS, in which all
symbols represent the same meaning as the symbols described in the specifi-
cation. A drug is also provided, which containing, as an active ingredient, a
compound having GBA1 and GCS dual modulatory activity in prevention and/
or treatment of a disease associated with GBA1 and/or GCS.

WO 2024/179491 A1